MBRX Earnings Date: Nov 12, 2026 (Estimated) — Moleculin Biotech, Inc.
NASDAQ
Updated
When is MBRX's next earnings date?
Moleculin Biotech, Inc. (MBRX) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$8.87.
How did MBRX do in its last earnings report?
In its most recent report on Aug 14, 2026 (Q2 2026), Moleculin Biotech, Inc. posted EPS of -$28.00 versus the -$31.00 estimate, a beat of 9.7%. Revenue was $0. The stock's 1-day post-earnings move was +7.1%.
How much does MBRX stock move after earnings?
MBRX beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.0% (up or down) in the day after earnings.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | -31.00 | -28.00 | +9.68% | $0 | ✅ Beat | +7.09% | +3.32% | +35.61% |
| 2026-08-13 | -31.00 | -28.00 | +9.68% | — | ✅ Beat | +17.24% | +9.58% | +36.97% | |
| 2026-05-15 | Q1 2026 | -33.40 | -70.80 | -111.98% | $0 | ❌ Miss | -4.09% | +8.64% | +23.18% |
| 2026-03-19 | Q4 2025 | -135.40 | -521.20 | -284.93% | $0 | ❌ Miss | -0.96% | +19.71% | +16.35% |
| 2025-11-13 | Q3 2025 | -4.40 | -13.60 | -209.09% | $0 | ❌ Miss | -4.41% | -7.14% | -60.35% |
| 2025-08-12 | Q2 2025 | -3.20 | -9.80 | -206.25% | $0 | ❌ Miss | +1.93% | -9.97% | -43.37% |
| 2025-03-21 | Q4 2024 | -26.60 | -7.40 | +72.18% | $0 | ✅ Beat | -2.75% | -4.59% | -3.67% |
| 2024-11-08 | Q3 2024 | -48.80 | -57.00 | -16.80% | $0 | ❌ Miss | -1.57% | +6.27% | -9.41% |
Showing last 8 quarters.